We are live on
!
Find out more
KXA
KPCB XV Associates Portfolio holdings
AUM
$35.8M
1-Year Est. Return
57.59%
This Fund
S&P 500
This Quarter
Est. Return
+26.96%
1 Year Est. Return
-57.59%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$233M
AUM Growth
–
Cap. Flow
+$239M
Cap. Flow
% of AUM
102.7%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
4
New
4
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Twilio
TWLO
|
+$117M |
| 2 |
RAPT
RAPT Therapeutics
RAPT
|
+$52.9M |
| 3 |
Upstart Holdings
UPST
|
+$34.8M |
| 4 |
Atara Biotherapeutics
ATRA
|
+$34.7M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 54.29% |
| 2 | Healthcare | 32.35% |
| 3 | Financials | 13.36% |
Similar funds
ALFIA
KCGDR
FCMI
PIM
FCOMV
SEM
MCMI
LCM
KPCB XV Associates's Q4 2020 Portfolio in Review
Q4 2020 is the first quarter with a 13F filing on record for KPCB XV Associates, which disclosed 4 positions worth $233M. Its ten largest holdings account for 100% of the portfolio.
Its largest position is Twilio: 373,333 shares worth $126M.
By sector, the portfolio is most concentrated in Technology at 54% of assets, followed by Healthcare and Financials.
- KPCB XV Associates's largest Q4 2020 buy was Twilio: 373,333 shares worth $126M.
- KPCB XV Associates's ten largest holdings make up 100% of its $233M portfolio in Q4 2020.
- KPCB XV Associates disclosed 4 positions in Q4 2020, its first 13F filing on record.
Based on KPCB XV Associates's 13F filing for Q4 2020, filed 16 Feb 2021.